Table 1. Patient's characteristics and response by treatment.
| Patients | Sex | Age (years) | Previous therapies | Cetuximab line | Regimen | Best response | Duration of response (weeks) |
|---|---|---|---|---|---|---|---|
| 1 | F | 65 | FOLFOX | 2nd | CPT11-b/r+cetuximab (CT) | PR | 8 |
| 2 | M | 67 | FOLFOX; CPT11 | 3rd | CPT11-b/r+cetuximab | PD | NA |
| 3 | M | 60 | FOLFOX; CAP; FOLFIRI | 4th | CPT11-b/r+cetuximab (CT) | PD | NA |
| 4 | M | 82 | CAPOX | 2nd | CPT11-b/r+cetuximab (CT) | PD | NA |
| 5 | M | 78 | CAP; FOLFOX; FOLFIRI | 4th | CPT11-b/r+cetuximab (CT) | PD | NA |
| 6 | F | 63 | CPT11 | 2nd | CPT11-b/r+cetuximab (CT) | PD | NA |
| 7 | M | 72 | CPT11 | 2nd | CPT11-b/r+cetuximab (CT) | PD | NA |
| 8 | F | 59 | FOLFIRI | 2nd | CPT11-b/r+cetuximab (CT) | PR | 48 |
| 9 | M | 69 | FOLFIRI | 2nd | CPT11-b/r+cetuximab (CT) | PR | 16 |
| 10 | M | 59 | FOLFOX; FOLFIRI | 3rd | CPT11-b/r+cetuximab | PR | 48 |
| 11 | M | 67 | FOLFOX; CPT11 | 3rd | CPT11-b/r+cetuximab (CT) | PD | NA |
| 12 | M | 69 | FOLFOX | 2nd | CPT11-b/r+cetuximab (CT) | PD | NA |
| 13 | M | 79 | CAPOX; CPT11 | 3rd | CPT11-b/r+cetuximab | PR | 13 |
| 14 | M | 65 | None | 1st | CAPOX+cetuximab (CT) | PD | NA |
| 15 | F | 75 | CAPOX; FOLFIRI | 3rd | CPT11-b/r+cetuximab | PD | NA |
| 16 | M | 64 | 5FU; CAPOX; FOLFIRI | 4th | CPT11-b/r+cetuximab (CT) | PR | 12 |
| 17 | M | 72 | FOLFOX; CAPIRI | 3rd | CPT11-b/r+cetuximab (CT) | PR | 28 |
| 18 | F | 72 | 5FU/LV; CPT11 | 3rd | CPT11-b/r+cetuximab (CT) | SD | 8 |
| 19 | M | 66 | CAPIRI; CPT11 | 3rd | CPT11-b/r+cetuximab | PD | NA |
| 20 | F | 63 | None | 1st | CAPOX+cetuximab (CT) | PR | 8 |
| 21 | F | 84 | CAP; CPT11 | 3rd | CPT11-b/r+cetuximab | PD | NA |
| 22 | M | 59 | CAPOX/BV; FOLFIRI | 3rd | CPT11-b/r+cetuximab | SD | 1 |
| 23 | M | 78 | FOLFOX; CPT11 | 3rd | CPT11-b/r+cetuximab | PD | NA |
| 24 | F | 29 | FOLFOX; FOLFIRI | 3rd | CPT11-b/r+cetuximab (CT) | SD | 16 |
| 25 | M | 58 | FOLFOX; CPT11 | 3rd | CPT11-b/r+cetuximab | PR | 16 |
| 26 | M | 70 | None | 1st | CAPOX+cetuximab (CT) | PR | 13 |
| 27 | F | 44 | None | 1st | CAPOX+cetuximab (CT) | PD | NA |
Abbreviations: BV, bevacizumab; CAP, capecitabine; CAPIRI, irinotecan and CAP; CAPOX, oxaliplatin and CAP; CPT11-b/r, irinotecan-based regimen; CT, clinical trial; F, female; 5FU, fluorouracil; FOLFIRI, irinotecan, 5FU and folinic acid; M, male; FOLFOX, oxaliplatin, 5FU and folinic acid; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease.